Compare BridgeBio Pharma Inc (BBIO) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Tenet Healthcare Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.97 (market cap $16.36B), while Tenet Healthcare Corporation trades at $262.25 (market cap $20.89B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | THC | |
|---|---|---|
Market Cap | $16.36B | $20.89B |
Sector | Health | Health |
52-Week High | $90.17 | $262.63 |
52-Week Low | $47.29 | $161.37 |
Enterprise Value | $18.14B | $31.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
Tenet Healthcare (THC) trades at $260.67, up 0.28% today, with strong technical momentum including a golden cross pattern and bullish moving average alignment. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $6.12 versus $4.26 forecast, maintaining a three-quarter earnings beat streak. Valuation metrics remain attractive with P/E of 10.03 and EV/EBITDA of 5.73, while profitability metrics show exceptional ROE of 53.31% and net margin of 9.9%.
The investment outlook remains positive with 81% analyst buy ratings and $281.44 consensus price target representing 8% upside. Key risks include policy headwinds in ACA exchanges and hospital segment challenges, though strong ambulatory growth provides offset. The stock presents a compelling value-growth combination with momentum characteristics, supported by institutional accumulation and positive earnings revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
